Global Nicotine Replacement Therapy Market Expected to Reach $103.4 Billion by 2028

Aug.04.2022
Global nicotine replacement therapy market is set to reach $103.4 billion by 2028 with a CAGR of 15.1%. Key players include Pfizer, J&J, and GlaxoSmithKline.

According to Zion Market Research, the global nicotine replacement therapy market size was $44.5 billion in 2021. By 2028, demand for the global nicotine replacement therapy market size and share is expected to reach $103.4 billion with a compound annual growth rate (CAGR) of 15.1%.


List of Key Players in the Nicotine Replacement Therapy Market:


Chipla Corporation.


Pfizer Inc.


Johnson Service Company


British American Tobacco Company


Philip Morris Products S.A. (part of the Altria Group)


Empire brand


Sorry, I cannot translate this phrase to English as it seems to be a name written in Chinese characters and there is no context provided to determine its meaning.


Japan Tobacco Inc.


Overview of the Nicotine Replacement Therapy Market


Nicotine replacement therapy, which involves using low-dose nicotine products like patches, inhalers, gums, sprays, and lozenges that do not contain harmful substances found in tobacco, is becoming increasingly popular among smokers. This approach aims to reduce or eliminate tobacco use, which is known to cause chronic health problems like lung cancer and asthma due to its high nicotine content. The rising popularity of NRT is driven largely by public awareness of the harmful effects of smoking. As smoking rates continue to rise worldwide, governments are implementing measures like the Affordable Care Act, insurance rules, and awareness campaigns to encourage smokers to quit. Additionally, advancements in NRT technology are leading more people to turn to cutting-edge products like heat-not-burn devices, sweet gums, and lozenges, which are expected to accelerate the adoption of NRT. However, one of the biggest obstacles to NRT market expansion is the ban on e-cigarettes.


Key industry insights and findings of the nicotine replacement therapy market report:


According to analysis shared by our research analysts, the market for nicotine replacement therapy is expected to grow at a CAGR of approximately 15.1% annually between 2022 and 2028.


According to initial research, the estimated value of the nicotine replacement therapy market in 2021 is approximately $44.5 billion, with a projected increase to around $103.4 billion by 2028.


The increase in smoking-related diseases and government measures supporting smoking, as well as the growing acceptance of electronic cigarettes and heated tobacco, are expected to have a positive impact on the development of the North American market.


The number of smokers complying with smoking bans in the region is on the rise, leading to a stronger demand for products such as chewing gum and inhalers. In addition, the smoking cessation rate in the United States is higher than in other countries, resulting in an increase in sales volume for these products.


According to a survey conducted by the Centers for Disease Control and Prevention (CDC), approximately 68% of Americans have decided to quit smoking. Therefore, it is expected that this will increase product sales in the coming years.


One major factor driving the growth of the global nicotine replacement therapy market is the increasing awareness of the dangers of smoking worldwide.


Industry news:


The Nicotine Replacement Therapy Market: Growing Driving Factors and an Increasing Understanding of the Detrimental Effects of Smoking are Driving Market Growth.


Public awareness of the harmful effects of smoking is expected to become a key market driver. More than 1.1 billion people worldwide smoke. Government initiatives, such as the Affordable Care Act, insurance requirements, and campaigns to raise awareness of the harmful effects of smoking through education, have contributed to the use of nicotine replacement therapies. Favorable reimbursement policies will further accelerate the global expansion of the nicotine replacement therapy market.


Despite widespread awareness of the negative effects of smoking spread through awareness programs, TV commercials, leaflets and other means, the number of people wanting to quit smoking has decreased. In addition, although successful NRT treatments have been introduced and public awareness has been improved, product intake rates are still very low. According to research by the World Health Organization (WHO), there are myths about these products. These include the belief that the products are ineffective, have negative effects, and are costly. As a result, current misconceptions about these items have reduced their adoption rates, leading to a decline in sales.


Global Nicotine Replacement Therapy Market: Segmentation. The global nicotine replacement therapy market has been segmented based on product, distribution channel, and geography.


The global market for nicotine replacement therapy products is classified into inhalers, chewing gum, transdermal patches, lozenges, sublingual tablets, e-cigarettes, and smokeless tobacco products. In 2021, e-cigarettes held the largest market share at 52.1%. It is expected that more and more people will become aware that e-cigarettes are safer than traditional cigarettes, especially among the younger generation, which will further drive market growth. The wide range of customizable options offered by suppliers, including temperature control and nicotine dosage, is expected to contribute to increased demand for the product. In addition, the rapidly growing technology of e-cigarettes has become increasingly popular, increasing user satisfaction.


The global market for nicotine replacement therapy is divided into offline and online distribution channels. In 2021, the offline sub-market had the highest revenue share at 83.9%. The growth of the sub-market is being fueled by the increase in NRT products such as transdermal patches, gels, gum, e-cigarettes, and heated tobacco products in retail chains like Walgreens and Walmart Stores, Inc. Additionally, the connection between hospitals and these retail chains is aiding in the expansion of the business.


In 2021, North America dominated the nicotine replacement therapy market.


The prevalence of smoking-related diseases, increased government support for smoking, and higher acceptance of electronic cigarettes and heated tobacco are expected to have a favorable impact on the development of the North American market. This region has the highest retail sales of NRT products in the United States and Canada. The number of smokers adhering to smoking bans in the region is increasing, leading to stronger demand for products such as gum and inhalers. Additionally, the smoking cessation rate in the United States is higher than in other countries, resulting in increased sales of these products. Approximately 68% of Americans have decided to quit smoking, according to a survey conducted by the Centers for Disease Control and Prevention (CDC), which is expected to increase product sales in the coming years. Additionally, in the United States, gum is more commonly used than other treatment methods for smoking cessation in the market.


Statement:


This article is compiled based on third-party information and is intended for industry exchange and learning purposes only.


This article does not represent the views of 2FIRSTS, and 2FIRSTS is unable to confirm the authenticity and accuracy of the article's content. The translation of this article is solely intended for industry professionals to exchange and conduct research.


Due to limitations in the level of translation, the translated article may not fully reflect the expression of the original article. Please refer to the original article for accuracy.


2FIRSTS maintains a consistent stance with the Chinese government on any domestic, Hong Kong, Macao, Taiwan, or foreign-related issues and statements.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us to request deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

New York directs Tax and Finance to build “Vapor Products” registry; products not listed deemed illegal
New York directs Tax and Finance to build “Vapor Products” registry; products not listed deemed illegal
New York Gov. Kathy Hochul says the state will crack down on illegal flavored vapes by creating a registry identifying which vapor products may be legally sold. The governor directed the state Department of Taxation and Finance to establish a “Vapor Products” registry, with products not on the list treated as illegal.
Jan.20 by 2FIRSTS.ai
Estonia warns of a booming illicit vape market, raising risks for minors and legitimate trade
Estonia warns of a booming illicit vape market, raising risks for minors and legitimate trade
Estonia’s Chamber of Commerce and Industry and the Tax and Customs Board are urging the government to address a thriving illicit vape market that undermines fair competition and makes vapes easily accessible to minors.
Feb.04 by 2FIRSTS.ai
PMI reports full-year 2025 results with net revenues of $40.6 billion and smoke-free net revenues were about $16.9 billion
PMI reports full-year 2025 results with net revenues of $40.6 billion and smoke-free net revenues were about $16.9 billion
Philip Morris International (PMI) released its Q4 and full-year 2025 results on February 6, 2026. PMI reported full-year net revenues of $40,648 million ($40.6 billion), reported diluted EPS of $7.26 and adjusted diluted EPS of $7.54. PMI said smoke-free net revenues were $16.9 billion and represented 41.5% of total net revenues, with smoke-free products available in 106 markets and over 43 million estimated adult consumers.
Feb.06 by 2FIRSTS.ai
Malaysia joint operation seized $19,000 worth of vape liquid in Likas
Malaysia joint operation seized $19,000 worth of vape liquid in Likas
More than 2,300 units of vape liquid worth over RM75,000 were seized during an integrated operation at premises in Likas near Kota Kinabalu. During Ops Taring Landai E-Cigarette Mega on Feb 10 night, the Marine Police, Sabah Health Department officials and district police detected a shop displaying 92 types of vape pods and, after further searches, found 2,353 units of vape liquid stored on the premises.
Feb.11 by 2FIRSTS.ai
Exclusive: Altria Confirms FDA Grants Marketing Authorization to on! PLUS, Ending More Than a Year of PMTA Review
Exclusive: Altria Confirms FDA Grants Marketing Authorization to on! PLUS, Ending More Than a Year of PMTA Review
Altria on December 19 confirmed that six on! PLUS nicotine pouch products had received U.S. FDA marketing authorization, ending a PMTA review lasting more than a year after the company moved ahead with launch plans before clearance.
Regulations
Dec.20
British American Tobacco to close South Africa cigarette plant by end-2026, citing illicit trade squeezing legal market
British American Tobacco to close South Africa cigarette plant by end-2026, citing illicit trade squeezing legal market
British American Tobacco South Africa (BATSA) said it will halt local production of factory-made cigarettes and close its manufacturing plant in Heidelberg, Gauteng by the end of 2026, shifting to an import-led supply model. The company said illicit cigarettes now account for about 75% of South Africa’s market, making local manufacturing “unsustainable” and putting around 230 jobs at risk.
Jan.16